Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024

PR Newswire06-21

SAN DIEGO, June 21, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2445754591?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/zfOjqiAZgW9N3e3xTlAHuQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/b14cd9a6b167a6a2e15f523d003ebf22","is_english":true,"pubTime":"2024-06-21 20:01","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2445754591","market":"us","top_or_hot":-1,"title":"Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024","media":"PR Newswire","content":"<div>\n<p>SAN DIEGO, June 21, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/aethlon-medical-release-fiscal-end-120100863.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-21 20:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/aethlon-medical-release-fiscal-end-120100863.html><strong>PR Newswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SAN DIEGO, June 21, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/aethlon-medical-release-fiscal-end-120100863.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4181","symbol_name":"酒店及度假村房地产投资信托","start_time":0,"source_url":"https://finance.yahoo.com/news/aethlon-medical-release-fiscal-end-120100863.html","article_id":"2445754591","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/zfOjqiAZgW9N3e3xTlAHuQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/b14cd9a6b167a6a2e15f523d003ebf22"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/aethlon-medical-release-fiscal-end-120100863.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2445754591","pubTimestamp":1718971260,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"SAN DIEGO, June 21, 2024 /PRNewswire/ --Aethlon Medical, Inc. , a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal year ended March 31, 2024, at 4:15 p.m. ET on Thursday, June 27, 2024.Interested parties without internet access or unable to pre-register may dial in by calling:. PARTICIPANT DIAL IN : 1-844-836-8741PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442. All callers should ask for the Aethlon Medical, Inc. conference call.A replay of the call will be available approximately one hour after the end of the call through July 27, 2024. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529  or 1-412-317-0088  or Canada toll free at 1-855-669-9658. The replay conference ID number is 6876352.Company Contact:Jim FrakesInterim Chief Executive Officer and Chief Financial OfficerAethlon Medical, Inc. Jfrakes@aethlonmedical.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4181":"酒店及度假村房地产投资信托","BK4588":"碎股","AEMD":"Aethlon Medical Inc","IDE":"Voya Infrastructure Industrials and Materials Fund","BK4082":"医疗保健设备","BK4218":"酒店及度假村房地产信托","HST":"美国豪斯特酒店","BK4585":"ETF&股票定投概念","BK4568":"美国抗疫概念","BK4583":"猴痘概念"},"translate_title":"Aethlon Medical将于2024年6月27日发布财年末财务业绩并举办电话会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AEMD":1,"HST":1,"IDE":1},"content_text":"SAN DIEGO, June 21, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal year ended March 31, 2024, at 4:15 p.m. ET on Thursday, June 27, 2024.\nManagement will host a conference call on Thursday, June 27, 2024, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.\nInterested parties can register for the conference by navigating to https://dpregister.com/sreg/10190237/fce977aef1. Please note that registered participants will receive their dial-in number upon registration.\nInterested parties without internet access or unable to pre-register may dial in by calling:\nPARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442\nAll callers should ask for the Aethlon Medical, Inc. conference call.\nA replay of the call will be available approximately one hour after the end of the call through July 27, 2024. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 6876352.\nAbout Aethlon and the Hemopurifier®Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.\nAdditional information can be found at www.AethlonMedical.com.\nCompany Contact:Jim FrakesInterim Chief Executive Officer and Chief Financial OfficerAethlon Medical, Inc. Jfrakes@aethlonmedical.com\nInvestor Contact:Susan NoonanS.A. Noonan Communications, LLCsusan@sanoonan.com\n View original content:https://www.prnewswire.com/news-releases/aethlon-medical-to-release-fiscal-year-end-financial-results-and-host-conference-call-on-june-27-2024-302178802.html\nSOURCE Aethlon Medical, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2445754591"}